Therapeutic developments in MS: report from the 57th Annual Meeting of the American Academy of Neurology (AAN), 9-15 April 2004, Miami, Florida, USA.
Over 6000 neurologists and neuroscientists from around the world gathered in April at the 57th Annual Meeting of the American Academy of Neurology (AAN). There were several scientific platform sessions devoted to MS at the meeting, concentrating on recent clinical trials (including new natalizumab data), outcomes assessment, imaging, surrogate markers and mechanism of action of current therapeutics. During the meeting, the 2005 John Dystel Prize for MS Research was awarded to Jack Antel of McGill University, Montreal, Canada. Professor Antel was honoured for his major contributions to research into interactions between the immune system and the brain, and its application to MS, and for his role as a leading MS clinician and investigator. Additional activities devoted to MS were posters, educational courses and seminars covering a wide variety of topics. This report focuses on some of the key studies presented in the field of therapeutic developments in MS.
Clanet
Michel
M
D006266:Health Education; D006801:Humans; D009103:Multiple Sclerosis / Q000628:therapy*; D009462:Neurology / Q000379:methods*